Avana

Product Overview

Avana is a prescription medication containing the active component Avanafil. As a selective phosphodiesterase type 5 (PDE5) inhibitor, it is clinically approved for managing erectile dysfunction (ED) in adult males. The medication enhances penile blood circulation during sexual arousal, facilitating the attainment and sustenance of an erection.

Therapeutic Applications

This pharmaceutical agent is specifically indicated for the treatment of erectile dysfunction, a medical condition where patients experience difficulty achieving or maintaining penile erection adequate for satisfactory sexual performance. It is contraindicated for pediatric use and female patients.

Administration Guidelines

The oral tablet should be consumed approximately 30 minutes prior to anticipated sexual intercourse. Administration with food is permissible, though grapefruit products should be strictly avoided due to potential pharmacokinetic interactions that may elevate adverse effect risks.

Mechanism of Action

Avana exerts its therapeutic effect through selective inhibition of phosphodiesterase type 5 (PDE5), an enzyme responsible for cGMP degradation in penile tissues. This inhibition promotes vascular smooth muscle relaxation, thereby increasing blood flow to the corpus cavernosum and supporting erectile function during sexual stimulation.

Dosage Protocol

The initial recommended dosage is 100 mg administered orally prior to sexual activity (minimum 30 minutes before). Dosage adjustments between 50-200 mg may be implemented based on individual efficacy and tolerability profiles. Strict adherence to a maximum single daily dose is imperative, with a mandatory 24-hour interval between administrations.

Therapeutic Advantages

• Facilitates attainment and maintenance of clinically sufficient erections
• Demonstrates rapid pharmacokinetic onset (typically ≤30 minutes)
• Exhibits food-independent absorption characteristics
• Provides a viable therapeutic alternative for ED management

Adverse Effect Profile

Common pharmacologically expected reactions may include cephalalgia, vertigo, facial flushing, rhinitis, lumbar discomfort, and dyspepsia. These transient effects typically resolve spontaneously. Persistent or severe reactions warrant immediate medical consultation.

Important Precautions

• Contraindicated in patients with known hypersensitivity to Avanafil or excipient components
• Absolute contraindication with concurrent nitrate therapy or specific antiretroviral regimens
• Exercise caution when engaging in activities requiring alertness due to potential neurocognitive effects

Storage Conditions

Maintain at controlled room temperature (20-25°C) in a dry environment protected from light exposure. Ensure secure storage away from pediatric and animal access. Discard any medication beyond the labeled expiration date.

Medical Disclaimer:

The provided information represents curated, medically-reviewed content intended for educational purposes only. This material should not supersede professional medical advice, diagnosis, or treatment. The content may not encompass all potential adverse effects, contraindications, or drug interactions. Patients must consult qualified healthcare providers regarding any medical condition or therapeutic regimen. This information aims to complement, not replace, the essential physician-patient relationship.